An experimental drug meant for colorectal cancer developed by Woburn's ArQule Inc. as well as by Japan's Daiichi Sankyo Co. Ltd. has failed to show any degree of improvement in patient's health.
The revelation had direct impact on the shares of ArQule, as they straight went down by 18%. Earlier, the company shares were down by 15% but with progress of time, the loss increased.
To talk about the trial that did not turn out to be successful. The trial had 122 patients, who were diagnosed with relapsed colorectal cancer. Assessment report of drug's efficacy revealed that the drug was not effective at all. However, it shall also be noted that the experimental drug also failed to show any sort of improvement in comparison to the other drug tivantinib.
Industry experts have different opinions about the decline in shares. Adnan Butt, an analyst at the RBC Capital Markets said that he would like to term the decline in shares to be an overreaction.
Sources known to the matter were of the view that the drug known as tivantinib was able to reduce the tumor's growth by a slight difference. "We plan to continue discussions. To determine how best to proceed with further clinical development of tivantinib in this tumor type", said Reinhard von Roemeling, head of clinical development for cancer treatments at Daiichi.
Source: http://topnews.us/content/252636-colorectal-cancer-s-experimental-drug-fails-preliminary-trial
oscar winners 2012 billy crystal oscars 2012 angelina jolie oscars chardon high school christopher plummer viola davis school shooting in ohio
কোন মন্তব্য নেই:
একটি মন্তব্য পোস্ট করুন